Jefferies initiated coverage of Rocket Pharmaceuticals (RCKT) with a Buy rating and $29 price target The company has five potentially best- and first-in-class, curative gene therapies in the clinic for fatal rare diseases with no approved therapies, the analyst tells investors in a research note. The firm’s thesis centers on RP-A501, which it says has a high 65%-75% chance to succeed in a pivotal Phase II study in 2025 for Danon heart disease. The data could push Rocket shares up 100%, implying a favorable risk/reward, contends Jefferies.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals price target lowered to $40 from $44 at Leerink
- Rocket Pharmaceuticals 13.2M share Spot Secondary priced at $12.50
- Closing Bell Movers: Dave & Busters down 11% after Q3 miss
- Rocket Pharmaceuticals announces $150M common stock offering
- Rocket Pharmaceuticals Advances Genetic Therapies Pipeline